CRDL — Cardiol Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$123.09m
- CA$92.67m
Annual income statement for Cardiol Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.079 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 20.7 | 38.7 | 41.3 | 29.8 | 40.3 |
| Operating Profit | -20.7 | -38.7 | -41.3 | -29.8 | -40.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20.6 | -31.6 | -30.9 | -28.1 | -36.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -20.6 | -31.6 | -30.9 | -28.1 | -36.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -20.6 | -31.6 | -30.9 | -28.1 | -36.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20.6 | -31.6 | -30.9 | -28.1 | -36.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.691 | -0.732 | -0.495 | -0.436 | -0.512 |